In vivo, combined treatment with Apigenin and 5-FU confirmed significant growth inhibition of hepatocellular carcinoma (HCC) xenograft tumors via activation of the mitochondrial pathway of apoptosis, indicated by activation of caspase 3 and PARP and a decrease in Bcl-2 levels. The gene discussed is BCL2; the disease is hepatocellular carcinoma.